Vertex shares jump on positive telaprevir data

Vertex Pharmaceuticals got a much-needed boost to its share price after investors responded positively to the latest data analysis on its closely-watched hepatitis C therapy. Vertex stock jumped 28 percent after researchers noted that patients responded to telaprevir in a mid-stage study. The data will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the European Association for the Study of the Liver in Milan, April 23-27. There's a $3 billion market for hep C drugs in the U.S. and Europe. Schering-Plough is also developing a hep C drug--boceprevir.

- check out the press release
- read the AP report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.